Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Fujifilm, Merck Partner on $60M Microbial Biologics Facility | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Fujifilm, Merck Partner on $60M Microbial Biologics Facility

New 20,000-liter facility to be used by Fujifilm for its contract development and manufacturing customers

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Fujifilm Diosynth Biotechnologies, a global biologics contract development and manufacturing organization (CDMO), said that it is in the process of establishing a long-term collaboration with Merck to invest in and operate a new 20,000 liter large-scale microbial-biologics facility for supply of active pharmaceutical ingredient (API) to its customers.

This collaboration involves a $60 million investment by Merck at its Brinny manufacturing plant in Innishannon, County Cork, Ireland. Merck in Brinny has been in operation for more than 30 years and is an integrated site for the development, testing and manufacturing of biologics.

It is intended that the large-scale biologics operations at Merck in Brinny will be operational in early 2018 for biotech and pharma customers of Fujifilm Diosynth.

The deal addresses a market need for large-scale microbial biologics manufacturing and complements Fujifilm Diosynth’s existing microbial capacity that ranges from 100L up to 5000L both in the U.S. and UK.

According to the company, microbial fermentation remains vital technology for the process of manufacturing biologics, and this investment, drawing on the latest production advances, will enable Fujifilm Diosynth’s existing and future customers to have a clear and secure line-of-sight to higher product volumes along with lower cost-of-goods. The latter is particularly important as products enter late clinical phase and commercialization.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics